ALLO
Source profileAllogene Therapeutics
Allogeneic cell therapy
Company profile
CIK1737287
ExchangeNASDAQ
SectorHealthcare
Tracked assets1
Pipeline assets
Cema-cel
Large B-cell lymphoma
Phase 2Investor Day
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Cell therapy pipeline investor update Investor Day | Cema-cel | Phase 2 | July 24, 2026 | exact | upcoming |
SEC filings
No sample filings for this company.
Press releases
ClinicalTrials.gov studies
No linked sample studies for this company.